Our findings are in line with previous in vitro studies from our group on BCP-ALL cells which showed that, although CD22 expression was essential for InO binding, efficacy was not dependent on CD22 expression levels, while a clear correlation with calicheamicin sensitivity was noticed [9]. Here, CD22 is linked to acute lymphoblastic leukemia.